The global digital therapeutics market is expected to reach US$ 8,941.1 Mn by 2025 from US$ 1,993.2 Mn in 2017. The market is estimated to grow with a CAGR of 20.8% during the forecast period from 2018 to 2025.
Global digital therapeutics market is expected to grow in the coming years, owing to the rising pressure on healthcare providers to reduce healthcare cost in the market. The fiscal pressure and patent cliffs compel healthcare providers to cut on drug prices, encourage the use of generics and scale back the reimbursement. This in turn is gradually reducing the profit margins and annual net sales of the healthcare companies that leads to immediate requirement of a strategic plan so as to cut down on the operational costs.
Get PDF sample copy: https://www.theinsightpartners.com/sample/TIPHC00002236/
The major players operating in the digital therapeutics market include Propeller Health, CANARY HEALTH, Noom, Inc., 2Morrow Inc., Livongo Health, Proteus Digital Health, WellDoc, Inc., Fitbit, Inc., Omada Health, Inc., and MANGO HEALTH and among others.
The market players are focused towards bringing new and innovative program and product launches to sustain their position in the market. For instance, in November 2017, Fitbit, Inc. launched in Argentina with its Fitbit Versa, Fitbit Ionic and Fitbit Ionic adidas Edition smart watches and Fitbit Charge 3 fitness tracker devices. Additionally, in September 2018, Fitbit, Inc. launched Fitbit Care device that combines health coaching and virtual care through the new Fitbit Plus app.
Rising pressure on healthcare providers to reduce healthcare costs is anticipated to drive the market for digital therapeutics over the forecast period.
Global digital therapeutics market, based on the application is segmented into diabetes, cardiovascular disease, central nervous system disease, respiratory diseases, smoking cessation, musculoskeletal disease and others. In 2017, diabetes segment held the largest share, by application. The segment is also anticipated to grow at a significant rate during the forecast period, since there has been an increase in the incidence of diabetes across the globe.
Inquire for Discount: https://www.theinsightpartners.com/discount/TIPHC00002236/
Product launch/update and partnerships were observed as the most adopted strategy in global digital therapeutics industry. Few of the product approvals and partnerships made by the players in the market are listed below:
2017: In November, Propeller Health and Express Scripts entered into a partnership to provide Propeller's FDA-cleared digital solutions to Express Scripts to manage asthma or COPD.
2016: In November, Propeller Health received FDA approval for its Propeller platform for use with GSK's Ellipta inhaler.
2018: In April, Canary Health entered into a partnership with NMRHCA to offer the Better Choices, Better Health (BCBH) digital therapeutics program in New Mexico.
2016: In June, Canary Health partnered with Medtronic to expand their diabetes care offerings with Canary Health-s self-management suite for pre-diabetes, diabetes and related comorbidities.